Eli Lilly stock sits 1.19 percent below its 52-week high
Published on 10/15/2026 at 11:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRecent company developments
- Lilly listed new Phase 3b data among its latest developments on October 9, 2026.
- Second-quarter revenue reached USD 22.97 billion, up 47.70 percent year over year.
- Eli Lilly stock trades at EUR 1,093.80 at 11:04 a.m. CEST at Lang & Schwarz on October 15, 2026, 0.51 percent above the Xetra close of October 14, 2026.
Eli Lilly and Co. (ISIN US5324571083) was trading at EUR 1,093.80 at Lang & Schwarz on October 15, 2026, 0.51 percent above the Xetra close of October 14, 2026. The company’s latest listed development was new Phase 3b data on October 9, 2026, according to Eli Lilly and Company. For investors, the next earnings update is the more immediate test of whether the company can sustain its rapid sales growth.
Revenue growth sets a high bar
In the second quarter of 2026, revenue reached USD 22.97 billion, up 47.70 percent from the same quarter a year earlier, according to MarketBeat. The same report cited 2026 earnings-per-share guidance of USD 35.50 to USD 36.50, leaving the October report with a clear benchmark.
Three developments shape the backdrop
On October 2, 2026, Lilly listed an expanded indication for Jaypirca. On October 5, 2026, it outlined 21 dermatology presentations for Fall Clinical 2026. On October 9, 2026, it listed new Phase 3b data on Taltz and Zepbound. Each item appeared in the company’s investor update, Eli Lilly and Company.
What does the next report test?
The next earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT, according to Eli Lilly and Company. The key comparison will be whether revenue momentum and the company’s earnings outlook remain consistent with the second-quarter base.
Stock stays near its yearly peak
The Lang & Schwarz price is EUR 13.20 below the 52-week high of EUR 1,107.00, a gap of 1.19 percent. That leaves the current quotation close to its yearly peak while the next company report approaches.
Eli Lilly and Co. was trading at EUR 1,093.80 at Lang & Schwarz on October 15, 2026, at 11:04 a.m. CEST, 0.51 percent above the Xetra close of October 14, 2026 (EUR 1,088.20). The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co stock.
Eli Lilly stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 15, 2026, 11:04 a.m. CEST): EUR 1,093.80
- Change versus Xetra close: plus 0.51 percent
- Xetra close (October 14, 2026): EUR 1,088.20
- Market capitalization: EUR 1,031.4 billion (as of October 15, 2026)
- 52-week range: EUR 662.90-1,107.00 (as of October 15, 2026)
- Sector / Industry: Healthcare / Pharmaceuticals
Market context: Market report S&P 500.
